150 related articles for article (PubMed ID: 30355421)
1. Pulmonary toxicity associated with pomalidomide.
Gajic S; Callahan EC; Brown JK; Elicker B; Ley B; Blanc PD
Int J Tuberc Lung Dis; 2018 Nov; 22(11):1383-1386. PubMed ID: 30355421
[TBL] [Abstract][Full Text] [Related]
2. Acute lung toxicity related to pomalidomide.
Geyer HL; Viggiano RW; Lacy MQ; Witzig TE; Leslie KO; Mikhael JR; Stewart K
Chest; 2011 Aug; 140(2):529-533. PubMed ID: 21813533
[TBL] [Abstract][Full Text] [Related]
3. Reversible pulmonary toxicity due to lenalidomide.
Coates S; Barker A; Spurgeon S
J Oncol Pharm Pract; 2012 Jun; 18(2):284-6. PubMed ID: 21742815
[TBL] [Abstract][Full Text] [Related]
4. Acute Liver Failure Associated With Pomalidomide Therapy for Multiple Myeloma.
Reed-Guy L; Hoteit MA; Garfall AL
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):e337-e338. PubMed ID: 29907543
[No Abstract] [Full Text] [Related]
5. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
Lacy MQ; Tefferi A
Leuk Lymphoma; 2011 Apr; 52(4):560-6. PubMed ID: 21338284
[TBL] [Abstract][Full Text] [Related]
6. Pomalidomide. A last-line treatment option for multiple myeloma.
Prescrire Int; 2014 Nov; 23(154):257-9. PubMed ID: 25954788
[TBL] [Abstract][Full Text] [Related]
7. Pomalidomide in heavily pretreated refractory multiple myeloma: a case report.
Palmas A; Piras G; Uras A; Asproni R; Murineddu M; Monne M; Stradoni R; Latte G
Future Oncol; 2017 Feb; 13(5s):7-9. PubMed ID: 28116939
[TBL] [Abstract][Full Text] [Related]
8. Thalidomide-induced bronchiolitis obliterans organizing pneumonia in a patient with multiple myeloma.
El Ati Z; Lamia R; Cherif J; Jbali H; Fatma LB; Mami I; Khedher R; Smaoui W; Krid M; Hamida FB; Beji S; Zouaghi MK
Saudi J Kidney Dis Transpl; 2019; 30(4):974-977. PubMed ID: 31464258
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma.
Gueneau P; Chretien ML; Cransac-Miet A; Aho LS; Lafon I; Favennec C; Guy J; Caillot D; Boulin M
Eur J Haematol; 2018 May; 100(5):518-525. PubMed ID: 29393533
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide-induced interstitial lung disease.
Chen Y; Kiatsimkul P; Nugent K; Raj R
Pharmacotherapy; 2010 Mar; 30(3):325. PubMed ID: 20180616
[TBL] [Abstract][Full Text] [Related]
11. Pomalidomide-induced lung injury: A case report.
Vivien A; Ancel J; Godet S; Dury S; Perotin JM; Deslee G; Launois C
Medicine (Baltimore); 2023 Jan; 102(2):e32473. PubMed ID: 36637962
[TBL] [Abstract][Full Text] [Related]
12. A case of lenalidomide-induced hypersensitivity pneumonitis.
Lerch E; Györik S; Feilchenfeldt J; Mazzucchelli L; Quadri F
Onkologie; 2010; 33(5):249-52. PubMed ID: 20502059
[TBL] [Abstract][Full Text] [Related]
13. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.
Streetly MJ; Gyertson K; Daniel Y; Zeldis JB; Kazmi M; Schey SA
Br J Haematol; 2008 Apr; 141(1):41-51. PubMed ID: 18324965
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide-induced pneumonitis.
Wyplosz B; Lerolle U; Israël-Biet D; Dougados J; Lillo-Le Louët A; Ghez D; Pouchot J
Eur J Intern Med; 2008 Nov; 19(7):e57-8. PubMed ID: 19013366
[No Abstract] [Full Text] [Related]
15. Pomalidomide in the management of relapsed multiple myeloma.
Touzeau C; Moreau P
Future Oncol; 2016 Sep; 12(17):1975-83. PubMed ID: 27283457
[TBL] [Abstract][Full Text] [Related]
16. Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma.
Conticello C; Parisi M; Romano A; Calafiore V; Ancora F; La Fauci A; Consoli ML; Di Raimondo F
Future Oncol; 2017 Feb; 13(5s):3-6. PubMed ID: 28116941
[TBL] [Abstract][Full Text] [Related]
17. Pomalidomide for the management of refractory multiple myeloma.
Summers BB; Cole SW; Olin JL
Am J Health Syst Pharm; 2014 Sep; 71(17):1443-8. PubMed ID: 25147167
[TBL] [Abstract][Full Text] [Related]
18. A case of acute kidney injury from crystal nephropathy secondary to pomalidomide and levofloxacin use.
Baird P; Leung S; Hoang H; Babalola O; Devoe CE; Wanchoo R; Jhaveri KD
J Oncol Pharm Pract; 2016 Apr; 22(2):357-60. PubMed ID: 25591868
[TBL] [Abstract][Full Text] [Related]
19. Pomalidomide.
Engelhardt M; Wäsch R; Reinhardt H; Kleber M
Recent Results Cancer Res; 2014; 201():359-72. PubMed ID: 24756804
[TBL] [Abstract][Full Text] [Related]
20. Pomalidomide: new immunomodulatory agent with potent antiproliferative effects.
Richardson PG; Mark TM; Lacy MQ
Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S36-44. PubMed ID: 23786844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
